Archive | Diagnostics and Tools Portfolio RSS feed for this section

FED Comments Focus On “Bubble” Stocks In Social Media and Biotech…. Update-1

Update 8PM EDT NASDAQ Holds Losses to 0.54%-Futures Stable Biotech Damage Across the Sector-Rayno Life Science Portfolio Notes Large Caps off about 2% (FBT), but Gilead (GILD) down only 0.95% and Roche (RHHBY) up 0.28%. Rayno Biopharma stocks all red down 3-4% with XBI down 3.86%, IBB down 2.2%. Damage not as severe in Diagnostics […]

Leave a comment Continue Reading →

Rayno Diagnostics and Tools Stocks: GHDX, ILMN, QGEN, RGDX.

Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014  on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]

Comments Off Continue Reading →

BIO 2014 Update #1 Personalized Medicine-Megatrend Momentum Continues

Challenges Ahead But Sequencing Is  A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of  Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage offering insights as to how the science driving personalized medicine is reshaping […]

Comments Off Continue Reading →

Market Perks Up on FED Testimony-Rates To Stay Low… Update 1 6/19

Update June 19.. 3:10 p EDT Ten Yr 2.62%, U.S.equities flat,biotech mixed, jobless claims down. Japanese and European equities up. Iraq on front page. GOLD Up $41 Breaks Through Resistance at $1300 Gold futures rose on technicals, Middle East turmoil, a weak dollar and a dovish FED. Silver is also strong.In this week’s Barron’s three […]

Comments Off Continue Reading →

Biotech Recap On a Down Day

NASDAQ Off 0.8%  On Disappointing Economic Data and Spiking Crude  Islamic militants took major cities in Iraq  causing a spike in oil to $106. The energy sector rallied 0.7% with many smaller players soaring over 4%. The energy sector is very strong up 10% YTD. Retails sales rose less than expected with a 0.3% increase […]

Comments Off Continue Reading →

Clinical Tools and Diagnostic Companies:Financial Metrics 2014 Q1Results

Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues: Abaxis (ABAX), Alere (ALR), Response Genetics (RGDX) and Quidel (QDEL). Q2 recovery will be key. […]

Comments Off Continue Reading →